Education
About Us
Working with TipRanks
Follow Us
Twist Bioscience Corp (TWST)
NASDAQ:TWST
TWST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.41 - $60.90
Previous CloseN/A
Volume152.02K
Average Volume (3M)1.09M
Market Cap
$2.41B
Enterprise Value$2.56B
Total Cash (Recent Filing)-$62.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.60
Next Earnings
May 01, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding59,651,142
10 Day Avg. Volume821,257
30 Day Avg. Volume1,090,160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.75
Price to Cash Flow (P/CF)-29.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.21
Enterprise Value/Ebitda-15.33
Forecast
1Y Price Target
$52.86Price Target Upside34.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Twist Bioscience News
PremiumCompany Announcements
Twist Bioscience Stockholders Approve Key Amendments
PremiumCompany Announcements
Twist Bioscience Reports Record Quarterly Revenue
PremiumCompany Announcements
Twist Bioscience’s Earnings Call Highlights Strong Growth---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageTwist Bioscience's low revenue exposure to China and limited exposure to US academic funding provides a competitive advantage.
Growth PotentialThe company's FY25 revenue guidance was raised, with significant contributions from the SynBio and BioPharma segments.
Revenue And EarningsTWST delivered a slight beat, with FY1Q25 revenue exceeding expectations and gross margin coming in particularly strong.
Bears Say
Market Share ConcernsThere are questions around TWST's continued ability to take market share at current levels, given an uncertain sector backdrop.
Sector OutlookThe outlook for the sector is likely to weigh on the shares in the near-medium term until R&D growth across pharma is more clear.
---
Ownership Overview
3.17% Insiders
28.32% Mutual Funds
0.08% Other Institutional Investors
41.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TWST FAQ
What was Twist Bioscience Corp’s price range in the past 12 months?
Twist Bioscience Corp lowest stock price was $27.41 and its highest was $60.90 in the past 12 months.
What is Twist Bioscience Corp’s market cap?
Twist Bioscience Corp’s market cap is $2.41B.
When is Twist Bioscience Corp’s upcoming earnings report date?
Twist Bioscience Corp’s upcoming earnings report date is May 01, 2025 which is in 30 days.
How were Twist Bioscience Corp’s earnings last quarter?
Twist Bioscience Corp released its earnings results on Feb 03, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.095.
Is Twist Bioscience Corp overvalued?
According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued.
Does Twist Bioscience Corp pay dividends?
Twist Bioscience Corp does not currently pay dividends.
What is Twist Bioscience Corp’s EPS estimate?
Twist Bioscience Corp’s EPS estimate is -0.55.
How many shares outstanding does Twist Bioscience Corp have?
Twist Bioscience Corp has 59,651,142 shares outstanding.
What happened to Twist Bioscience Corp’s price movement after its last earnings report?
Twist Bioscience Corp reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went up 0.726%.
Which hedge fund is a major shareholder of Twist Bioscience Corp?
Currently, no hedge funds are holding shares in TWST
---
Twist Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$52.86 (34.64% Upside)
$52.86 (34.64% Upside)
Blogger Sentiment
Bullish
TWST Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 110.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $156.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.42%
12-Months-Change
Fundamentals
Return on Equity
-37.73%
Trailing 12-Months
Asset Growth
-16.95%
Trailing 12-Months
Company Description
Twist Bioscience Corp
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
---
TWST Company Deck
---
TWST Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in revenue growth and gross margin improvement, driven by the SynBio and NGS segments. While there are challenges in the Biopharma segment and limited exposure to China, the company's strategic investments and innovative platform position it for future growth.Read More>---
TWST Stock 12 Month Forecast
Average Price Target
$52.86
▲(34.64% Upside)
Technical Analysis
Illumina
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Ginkgo Bioworks Holdings
―
Best Analysts Covering TWST
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
-21.21%
reiterated a sell rating 2 months ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of -21.21% per trade.
---